Frequency Therapeutics (NASDAQ:FREQ) posted its quarterly earnings data on Monday. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.05), Bloomberg Earnings reports. The firm had revenue of $24.24 million during the quarter.
FREQ stock opened at $16.16 on Thursday. Frequency Therapeutics has a 52-week low of $11.17 and a 52-week high of $17.44.
In related news, insider James E. Flynn purchased 285,714 shares of the business’s stock in a transaction on Monday, October 7th. The stock was acquired at an average price of $12.67 per share, for a total transaction of $3,619,996.38. Also, Director Marc A. Cohen purchased 17,857 shares of the business’s stock in a transaction on Monday, October 7th. The shares were bought at an average price of $12.84 per share, with a total value of $229,283.88.
Frequency Therapeutics Company Profile
Frequency Therapeutics, Inc, a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue.
Read More: What is the Quick Ratio?
Receive News & Ratings for Frequency Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frequency Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.